@oncostellae.com
Oncostellae is a biotechn startup developing small-molecule drugs with innovative scaffolds (NCEs) that modulate clinically validated therapeutic targets in oncology and inflammatory/autoimmune diseases.
๐ข
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Oncostellae is a biotech startup that specializes in developing small-molecule drugs using innovative scaffolds known as NCEs. They focus their efforts on modulating clinically validated therapeutic targets in the fields of oncology and inflammatory/autoimmune diseases. Established in 2013 by a team of experienced medicinal chemists and pharmacologists, Oncostellae boasts a strong foundation in drug discovery.
Their product pipeline includes proprietary drug candidates that hold strong intellectual property rights and global accessibility. These candidates are specifically designed to address unmet medical needs in the fields of oncology and immunology. Oncostellae's lead program, OST-122, is an orally taken GI-targeted JAK inhibitor being developed for the treatment of Inflammatory Bowel Disease (IBD).
This novel treatment exhibits excellent safety profiles and is undergoing phase 2a proof-of-concept studies in patients with Ulcerative Colitis. In addition to OST-122, Oncostellae is also developing OST-499, a non-steroidal full antagonist of the glucocorticoid receptor, for the treatment of colorectal cancer and other solid tumors. With a strong management team led by experienced professionals in the bio-pharmaceutical industry, Oncostellae is dedicated to bringing groundbreaking therapies to patients worldwide
Company Type
Privately Held
Company Size
11-50
Year Founded
2013
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere ๐
All services online
Top brand categories